Saturday, June 10, 2023
June 01 - 05, 2018; Chicago, Illinois
Medscape Oncology© WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
'An Inconvenient Truth': Add Bev or Chemo to TKIs in Lung Cancer
Is Upfront Combo Therapy Better Than the Sum of Its Parts?
Mark Kris: 'Don't Be Afraid to Use the Word "Cure" When It's Possible'
'Very Impressive' Overall Survival for Melanoma Combination
Does Immunotherapy Have a Role in
EGFR-Mutant Lung Cancer?
Are Oncology Pathways 'Achieving the Goals We Promised'?
New Biomarkers for Immunotherapy: The Microbiome and Beyond
In NSCLC, Immunotherapy Evolving to Become First-Line Treatment
Key Melanoma Trials at ASCO Yield Encouraging Survival Data
Immunotherapy Cost Problem May Require 'Revolutionary' Remedies
Cost Problem Only Getting Worse With IO Combos, Adjuvant Use
Clinical Pathways: Many Potential Benefits but 'More Work to Do'
CAR T-Cell Therapies: Broader Indications, Bigger Problems?
FDA's Genomic Screening Approval Blurs Research and Practice
The Best Ways to Dispel Patients' 'Cancer Myths' in Clinical Practice
Tumor Mutation Burden as Biomarker: All-Systems-Go or Too Early?
ASCO Data Establish Chemo-IO as Mainstay Frontline for NSCLC
Managing Patients' Belief That 'Precision Medicine Is a Panacea'
When Online Information Is the 'Third Party in the Exam Room'
Hype, Fear of Failure Driving Immunotherapy 'Hail Mary' Treatments
TAILORx Provides 'Clear Answer' for ER+ Breast Cancer
At ASCO, Noninferiority Trials Dominate, Prove 'Less Can Be More'
Skipping ASCO 2018? You're Not Alone (And Here's Why)
Top 5 Lung Cancer Presentations at ASCO 2018
Top Colorectal Cancer Studies at ASCO 2018
Long-Awaited TAILORx Results 'Will Impact Your Practice'
Gynecologic Cancer Studies to Look For at ASCO 2018
